Objective To observe the clinical efficacy of ICE and GDP regimens in the treatment of recurrent or refractory diffuse large B-cell lymphoma (DLBCL). Methods 60 cases of patients with recurrent or refractory DLBCL who were admitted to our hospital from January 2014 to January 2017 were selected for the study and were divided into control group and experimental group according to the random number table method. Control group was given ICE chemotherapy regimen, and experimental group was treated with GDP chemotherapy regimen. The clinical efficacy and adverse reactions after treatment were compared between the two groups. Results The total adverse reaction rate in observation group after chemotherapy was , which was significantly lower than that in control group (60.00% vs 83.33%) (P<0.05). There was no significant difference in clinical efficacy between the two groups after chemotherapy. Conclusion ICE and GDP regimens can have similar clinical efficacy in the treatment of recurrent or refractory DLBCL, but the latter one has less adverse reactions and can be better used in elderly patients and patients with combined heart disease, therefore the latter one is worthy of further promotion in clinical practice.